| Literature DB >> 30105241 |
Małgorzata Kępa1, Maria Miklasińska-Majdanik1, Robert D Wojtyczka1, Danuta Idzik1, Konrad Korzeniowski1, Joanna Smoleń-Dzirba1, Tomasz J Wąsik1.
Abstract
Phenolic compounds constitute one of the most promising and ubiquitous groups with many biological activities. Synergistic interactions between natural phenolic compounds and antibiotics could offer a desired alternative approach to the therapies against multidrug-resistant bacteria. The objective of the presented study was to assess the antibacterial potential of caffeic acid (CA) alone and in antibiotic-phytochemical combination against Staphylococcus aureus reference and clinical strains isolated from infected wounds. The caffeic acid tested in the presented study showed diverse effects on S. aureus strains with the minimum inhibitory concentration (MIC) varied from 256 μg/mL to 1024 μg/mL. The supplementation of Mueller-Hinton agar (MHA) with 1/4 MIC of CA resulted in augmented antibacterial effect of erythromycin, clindamycin, and cefoxitin and to the lesser extent of vancomycin. The observed antimicrobial action of CA seemed to be rather strain than antibiotic dependent. Our data support the notion that CA alone exerts antibacterial activity against S. aureus clinical strains and has capacity to potentiate antimicrobial effect in combination with antibiotics. The synergy between CA and antibiotics demonstrates its potential as a novel antibacterial tool which could improve the treatment of intractable infections caused by multidrug-resistant strains.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30105241 PMCID: PMC6076962 DOI: 10.1155/2018/7413504
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Antibiotic resistance profiles for tested Staphylococcus aureus strains.
| Strain | Cefoxitin Diameter of the Inhibition Zone [mm] | Methicillin resistance according to | Erythromycin Diameter of the Inhibition Zone [mm] | Clindamycin Diameter of the Inhibition Zone [mm] | Mechanism of Resistance to MLSB Antibiotics | The MIC of Vancomycin | Vancomycin resistance profile |
|---|---|---|---|---|---|---|---|
|
| 35 | MSSAb | 25 | 25 | - | 0.75 | Sf |
|
| 21 | MRSAc | 0 | 0 | cMLSBd | 0.38 | S |
|
| 31 | MRSA | 30 | 30 | - | 0.50 | S |
|
| 34 | MSSA | 25 | 25 | - | 0.75 | S |
|
| 32 | MSSA | 23 | 25 | - | 0.38 | S |
|
| 31 | MSSA | 0 | 25 | iMLSBe | 0.50 | S |
|
| 32 | MRSA | 25 | 27 | - | 0.50 | S |
|
| 13 | MRSA | 0 | 30 | iMLSB | 0.75 | S |
|
| 31 | MSSA | 30 | 35 | - | 0.38 | S |
|
| 32 | MRSA | 35 | 33 | - | 0.50 | S |
|
| 31 | MSSA | 30 | 35 | - | 0.38 | S |
|
| 30 | MRSA | 35 | 25 | - | 0.38 | S |
|
| 31 | MSSA | 10 | 22 | iMLSB | 0.38 | S |
|
| 31 | MSSA | 21 | 22 | - | 0.38 | S |
|
| 8 | MRSA | 0 | 0 | cMLSB | 0.75 | S |
|
| 14 | MRSA | 0 | 0 | cMLSB | 0.75 | S |
|
| 0 | MRSA | 0 | 0 | cMLSB | 0.75 | S |
|
| 21 | MRSA | 25 | 30 | - | 0.38 | S |
|
| 18 | MRSA | 0 | 0 | cMLSB | 0.50 | S |
|
| 11 | MRSA | 0 | 0 | cMLSB | 0.38 | S |
|
| 19 | MRSA | 25 | 30 | - | 0.50 | S |
|
| 14 | MRSA | 0 | 0 | cMLSB | 0.50 | S |
|
| 19 | MRSA | 0 | 0 | cMLSB | 0.38 | S |
Staphylococcus aureus 1 ÷ 20: strains from intractable surgical wounds.
bMSSA: methicillin-susceptible S. aureus.
cMRSA: methicillin-resistant S. aureus.
dcMLSB: constitutive macrolide, lincosamide, and type B streptogramin mechanism.
eiMLSB: inducible macrolide, lincosamide, and type B streptogramin mechanism.
fS: sensitive.
Antibacterial potential of caffeic acid (CA) alone and in antibiotic-phytochemical combination against Staphylococcus aureus. The combined effect of CA and antibiotics was evaluated using plates with MHA enriched with the subinhibitory concentration of CA.
| Strain | CAb MICc ( | Ed | E+CA | -Δ%e | DAf | DA+CA | -Δ% | FOXg | FOX+CA | -Δ% | VAh | VA+CA | -Δ% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 256 | 0.38 | 0.38 | 0 | 0.064 | 0.047 | -27 | 1 | 1 | 0 | 0.75 | 0.75 | 0 |
|
| 256 | 256 | 256 | 0 | 256 | 256 | 0 | 12 | 8 | -33 | 0.38 | 0.50 | -32 |
|
| 256 | 0.064 | 0.125 | 95 | 0.023 | <0.016 | -30 | 2 | 1 | -50 | 0.50 | 0.50 | 0 |
|
| 1024 | 0.50 | 0.25 | -50 | 0.064 | 0.032 | -50 | 2 | 1.5 | -25 | 0.75 | 0.50 | -33 |
|
| 512 | 0.50 | 0.38 | -24 | 0.064 | 0.064 | 0 | 0.75 | 0.75 | 0 | 0.38 | 0.75 | 97 |
|
| 512 | 256 | 0.19 | <-99.99 | 0.023 | <0.016 | -30 | 1.5 | 0.38 | -75 | 0.50 | 0.50 | 0 |
|
| 512 | 0.38 | 0.19 | -50 | 0.064 | 0.047 | -27 | 2 | 1 | -50 | 0.50 | 0.50 | 0 |
|
| 512 | 256 | 4 | -98 | 0.094 | 0.064 | -32 | 256 | 24 | -91 | 0.75 | 0.50 | -33 |
|
| 512 | 0.50 | 0.125 | -75 | 0.064 | <0.016 | -75 | 1.5 | 1.5 | 0 | 0.38 | 0.50 | 32 |
|
| 256 | 0.38 | 0.19 | -50 | 0.032 | 0.032 | 0 | 1 | 1 | 0 | 0.50 | 0.38 | -24 |
|
| 1024 | 0.19 | 0.19 | 0 | 0.032 | <0.016 | -50 | 1.5 | 0.50 | -67 | 0.38 | 0.38 | 0 |
|
| 512 | 0.38 | 0.19 | -50 | 0.064 | <0.016 | -75 | 1 | 1 | 0 | 0.38 | 0.38 | 0 |
|
| 512 | 32 | 3 | -91 | 0.047 | <0.016 | -66 | 2 | 0.75 | -63 | 0.38 | 0.38 | 0 |
|
| 1024 | 0.38 | 0.19 | -50 | 0.047 | 0.032 | -32 | 1.5 | 0.75 | -50 | 0.38 | 0.19 | -50 |
|
| 512 | 256 | 256 | 0 | 256 | 256 | 0 | 256 | 256 | 0 | 0.75 | 0.75 | 0 |
|
| 512 | 256 | 0.125 | <-99.99 | 256 | 0.094 | <-99.99 | 32 | 12 | -63 | 0.75 | 0.50 | -33 |
|
| 1024 | 256 | <0.016 | <-99.99 | 256 | <0.016 | <-99.99 | 256 | <0.016 | <-99.99 | 0.75 | <0.016 | -98 |
|
| 1024 | 0.25 | 0.19 | -24 | 0.064 | 0.023 | -64 | 8 | 1.5 | -81 | 0.38 | 0.38 | 0 |
|
| 1024 | 256 | 256 | 0 | 256 | 256 | 0 | 256 | 32 | -88 | 0.50 | 0.50 | 0 |
|
| 512 | 256 | <0.016 | <-99.99 | 256 | <0.016 | <-99.99 | 256 | <0.016 | <-99.99 | 0.38 | <0.016 | -96 |
|
| 512 | 0.38 | 0.094 | -75 | 0.047 | <0.016 | -66 | 6 | 0.75 | -88 | 0.50 | 0.50 | 0 |
|
| 1024 | 256 | 256 | 0 | 256 | 256 | 0 | 256 | 64 | -75 | 0.50 | 0.50 | 0 |
|
| 256 | 256 | <0.016 | <-99.99 | 256 | <0.016 | <-99.99 | 12 | <0.016 | <-99.99 | 0.38 | <0.016 | -96 |
| Median | 512 | 0.5 | 0.19 | -50 | 0.064 | 0.032 | -32 | 2 | 1 | -63 | 0.50 | 0.5 | 0 |
|
|
|
|
|
| |||||||||
a Staphylococcus aureus 1 ÷ 20: strains from intractable surgical wounds.
bCA: caffeic acid.
cMIC: minimum inhibitory concentration.
dE: erythromycin.
eMICs changes according to the formula [(MIC of antibiotic - MIC of antibiotic with CA) / MIC of antibiotic] x 100%.
fDA: clindamycin.
gFOX: cefoxitin.
hVA: vancomycin.
iWilcoxon Signed-Rank Test.